Valuation: OpGen Inc

Market Cap 113M 98.61M 91.79M 84.27M 159M 10.83B 162M 1.08B 425M 5.39B 426M 417M 18.08B P/E 2024
0.26x
P/E 2025 6.86x
Enterprise Value 115M 99.76M 92.85M 85.25M 161M 10.95B 163M 1.09B 430M 5.45B 431M 422M 18.29B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 2025-11-30
Chief Tech/Sci/R&D Officer 37 2025-03-31
Chief Operating Officer 54 2024-12-03
Director TitleAgeSince
Chairman 36 2024-08-01
Director/Board Member 39 2024-08-08
Director/Board Member 40 2024-08-08
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average +0.80%+1.05%+59.43%+103.27% 27.82B
Weighted average by Cap. -1.60%+2.03%+76.87%+128.10%

Financials

2024 2025
Net sales 5.2M 4.52M 4.2M 3.86M 7.29M 496M 7.4M 49.56M 19.45M 247M 19.51M 19.09M 828M 30.2M 26.25M 24.44M 22.43M 42.37M 2.88B 43.02M 288M 113M 1.44B 113M 111M 4.81B
Net income 11.99M 10.43M 9.7M 8.91M 16.82M 1.14B 17.08M 114M 44.89M 570M 45.04M 44.05M 1.91B 23.62M 20.53M 19.11M 17.55M 33.14M 2.25B 33.65M 225M 88.41M 1.12B 88.71M 86.76M 3.76B
Net Debt 711K 618K 575K 528K 997K 67.87M 1.01M 6.78M 2.66M 33.79M 2.67M 2.61M 113M 1.32M 1.14M 1.07M 978K 1.85M 126M 1.88M 12.56M 4.93M 62.57M 4.94M 4.84M 210M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-